Hengrui Pharma pays RMB 131 million to take over KiOmed knee osteoarthritis license

• Jiangsu Hengrui Pharmaceuticals agreed to take over KiOmedinevs One rights in mainland China, Hong Kong, Macau, Taiwan via novation of KiOmed license previously held by Hansoh parties.
• Transfer agreement sets RMB 131 million payment from Hengrui to Hansoh parties, including upfront amount plus potential regulatory milestone tied to change of domestic agent under NMPA marketing approval.
• License terms include up to EUR 51 million in potential sales and regulatory milestones payable to KiOmed.
• Royalty payments to KiOmed will be tiered based on future net sales of product.
• Transaction effective April 29, 2026; product received NMPA Class III medical device approval in 2025, not yet commercialized in territory.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260429-12137275), on April 29, 2026, and is solely responsible for the information contained therein.